Markusrunner
12/03/12 17:27
Ha respondido al tema
Threshold Pharmaceuticals, Inc (THLD): Opiniones
Lo siento jejeje es que uno se excita en exceso con el nasdaq!!! Esto he encontrado sobre ZLCS:
Zalicus (ZLCS)
Buy Limit: $2. Target Price: $7 in 2012.
ZLCS has one technology for pain pathways, and another that develops combinations of approved drugs to combat diseases. How do they do it? The company’s high-tech assay equipment identifies synergistic combinations between already-existing drugs in an effort to better target diseases.
In spite of the failure of their first two drugs, they merged with privately-held Neuromed in a deal that is very beneficial for both sides. Exalgo for pain was approved in 2010, and that roll out plus additional partnership announcements in 2011 will drive the stock higher.